Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Phase III MF studies evaluating parsaclisib + ruxolitinib in treatment naive & suboptimal responders

Abdulraheem Yacoub • 16 Apr 2021
AACR 2021
Myelofibrosis Myeloproliferative Neoplasms Parsaclisib Ruxolitinib

Abdulraheem Yacoub, MD, The University of Kansas Health System, Fairway, KA, details the rationale of two Phase III studies evaluating parsaclisib in patients with myelofibrosis (MF). The first study discussed by Dr Yacoub investigates the use of parsaclisib plus ruxolitinib in patients with myelofibrosis who have previously had suboptimal responses to ruxolitinib. The second study discussed tests this combination in patients with myelofibrosis who are JAK- and PI3K-inhibitor treatment-naive. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
2:45
The addition of venetoclax to HMAs for the treatment of CMML: a retrospective PSM analysis
Douglas Tremblay • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals